CD274 and non-small cell lung carcinoma: It alone has significantly improved overall survival (OS) compared with chemotherapy for first‐line NSCLC with PD‐L1 TPS ≥50%, 20%, ≥1%.5, 6, 24, 28 The higher the PD‐L1 expression, the better the objective response rate and median survival time.